We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
As the monkeypox virus has been spreading worldwide, causing a series of human health problems and even death, it becomes an important international public health issue. It is of vital importance to develop and manufacture high-efficient and safe vaccines for monkeypox. As a professional pre-clinical vaccine development and production server, Creative Biolabs has been engaged in the vaccine industry for over a decade. We combine traditional and updated technologies to help our global customers to design vaccine-based anti-monkeypox drug discovery solutions that address the urgent need for unmet treatment for monkeypox.
Vaccines are considered to be a safe and effective treatment to fight and eradicate viral infectious diseases. It is well known that the vaccine led to the eradication of smallpox, one of the most contagious and deadly diseases in humans. Monkeypox and smallpox are both poxviruses belonging to the family Poxviridae. As monkeypox is a global viral zoonosis, coordination of interventions between the human and wildlife health sectors is of vital importance. Previous and current monkeypox outbreaks have shown that people who have been vaccinated against smallpox have been infected with the monkeypox virus, indicating that the smallpox vaccine has limited protection against the monkeypox virus. Therefore, proper vaccination against monkeypox before or after recent exposure can be an effective tool to protect people from monkeypox diseases. JYNNEOS is administered as a live virus that is not replicate effective in human cells, thus enabling the human body to produce the appropriate antibodies to respond to the monkeypox virus. ACAM2000 is a live Vaccinia virus vaccine that is replication competent, and also used against smallpox. However, the limited supply and applicability to the population, the unknown side effects and protective effects of the vaccines, as well as the possible future mutations of the monkeypox virus have forced us towards the development of novel vaccines to address these issues.
Creative Biolabs offers a full range of vaccine-based anti-monkeypox drug discovery solutions to explore novel effective vaccines against monkeypox that have lower toxicity and fewer side effects. We combine traditional and cutting-edge technologies, including high-throughput screening, artificial intelligence, in vitro and in vivo platforms, and monkeypox detection services, to assist our global clients to discover effective vaccines against the monkeypox virus. We provide DNA and mRNA vaccine-based anti-monkeypox solutions, monkeypox-like particle-based vaccine solutions, as well as inactivated virus vaccine-based anti-monkeypox agent discovery solutions. If you have the intention to customize the vaccine-based anti-monkeypox drug discovery solutions, please don't hesitate to contact us.
To find more detailed information about our vaccine-based anti-monkeypox drug discovery solutions, please click the following links:
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.